Annual FCF
-$15.71 M
+$11.52 M+42.30%
December 31, 2024
Summary
- As of March 9, 2025, YMAB annual free cash flow is -$15.71 million, with the most recent change of +$11.52 million (+42.30%) on December 31, 2024.
- During the last 3 years, YMAB annual FCF has risen by +$87.81 million (+84.82%).
- YMAB annual FCF is now -40.73% below its all-time high of -$11.17 million, reached on December 31, 2016.
Performance
YMAB Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$1.87 M
+$8.79 M+82.47%
December 31, 2024
Summary
- As of March 9, 2025, YMAB quarterly free cash flow is -$1.87 million, with the most recent change of +$8.79 million (+82.47%) on December 31, 2024.
- Over the past year, YMAB quarterly FCF has increased by +$8.79 million (+82.47%).
- YMAB quarterly FCF is now -727.52% below its all-time high of $298.00 thousand, reached on June 30, 2024.
Performance
YMAB Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$15.71 M
+$6.17 M+28.18%
December 31, 2024
Summary
- As of March 9, 2025, YMAB TTM free cash flow is -$15.71 million, with the most recent change of +$6.17 million (+28.18%) on December 31, 2024.
- Over the past year, YMAB TTM FCF has increased by +$6.17 million (+28.18%).
- YMAB TTM FCF is now -137.80% below its all-time high of -$6.61 million, reached on March 31, 2018.
Performance
YMAB TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
YMAB Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +42.3% | +82.5% | +28.2% |
| 3 y3 years | +84.8% | +78.4% | +79.3% |
| 5 y5 years | +79.2% | +78.4% | +79.3% |
YMAB Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +84.8% | -727.5% | +94.5% | -25.2% | +84.8% |
| 5 y | 5-year | at high | +84.8% | -727.5% | +94.5% | -25.2% | +84.8% |
| alltime | all time | -40.7% | +84.8% | -727.5% | +94.5% | -137.8% | +84.8% |
Y-mAbs Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$15.71 M(-42.3%) | -$1.87 M(-82.5%) | -$15.71 M(-28.2%) |
| Sep 2024 | - | -$10.66 M(-3678.9%) | -$21.88 M(+74.3%) |
| Jun 2024 | - | $298.00 K(-108.6%) | -$12.55 M(-28.6%) |
| Mar 2024 | - | -$3.48 M(-56.7%) | -$17.59 M(-35.4%) |
| Dec 2023 | -$27.23 M(-64.1%) | -$8.04 M(+500.6%) | -$27.23 M(-2.2%) |
| Sep 2023 | - | -$1.34 M(-71.7%) | -$27.86 M(-39.1%) |
| Jun 2023 | - | -$4.73 M(-63.9%) | -$45.75 M(-28.6%) |
| Mar 2023 | - | -$13.12 M(+51.5%) | -$64.12 M(-15.5%) |
| Dec 2022 | -$75.92 M(-26.7%) | -$8.66 M(-55.0%) | -$75.92 M(-25.3%) |
| Sep 2022 | - | -$19.23 M(-16.7%) | -$101.58 M(+1.1%) |
| Jun 2022 | - | -$23.10 M(-7.3%) | -$100.49 M(+4.5%) |
| Mar 2022 | - | -$24.93 M(-27.4%) | -$96.19 M(-7.1%) |
| Dec 2021 | -$103.52 M | -$34.32 M(+89.1%) | -$103.52 M(+19.1%) |
| Sep 2021 | - | -$18.15 M(-3.5%) | -$86.94 M(-6.6%) |
| Jun 2021 | - | -$18.80 M(-41.7%) | -$93.05 M(-8.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$32.26 M(+81.9%) | -$101.89 M(+11.5%) |
| Dec 2020 | -$91.41 M(+21.1%) | -$17.74 M(-26.8%) | -$91.41 M(-8.0%) |
| Sep 2020 | - | -$24.25 M(-12.3%) | -$99.39 M(+2.3%) |
| Jun 2020 | - | -$27.64 M(+26.9%) | -$97.16 M(+16.2%) |
| Mar 2020 | - | -$21.78 M(-15.3%) | -$83.64 M(+10.8%) |
| Dec 2019 | -$75.46 M(+82.0%) | -$25.73 M(+16.9%) | -$75.46 M(+19.1%) |
| Sep 2019 | - | -$22.01 M(+55.9%) | -$63.37 M(+25.2%) |
| Jun 2019 | - | -$14.12 M(+3.7%) | -$50.60 M(+4.4%) |
| Mar 2019 | - | -$13.61 M(-0.2%) | -$48.46 M(+16.9%) |
| Dec 2018 | -$41.46 M(+161.3%) | -$13.63 M(+47.5%) | -$41.46 M(+49.0%) |
| Sep 2018 | - | -$9.24 M(-22.9%) | -$27.83 M(+49.7%) |
| Jun 2018 | - | -$11.98 M(+81.3%) | -$18.59 M(+181.3%) |
| Mar 2018 | - | -$6.61 M | -$6.61 M |
| Dec 2017 | -$15.87 M(+42.1%) | - | - |
| Dec 2016 | -$11.17 M | - | - |
FAQ
- What is Y-mAbs Therapeutics annual free cash flow?
- What is the all time high annual FCF for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics annual FCF year-on-year change?
- What is Y-mAbs Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics quarterly FCF year-on-year change?
- What is Y-mAbs Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics TTM FCF year-on-year change?
What is Y-mAbs Therapeutics annual free cash flow?
The current annual FCF of YMAB is -$15.71 M
What is the all time high annual FCF for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high annual free cash flow is -$11.17 M
What is Y-mAbs Therapeutics annual FCF year-on-year change?
Over the past year, YMAB annual free cash flow has changed by +$11.52 M (+42.30%)
What is Y-mAbs Therapeutics quarterly free cash flow?
The current quarterly FCF of YMAB is -$1.87 M
What is the all time high quarterly FCF for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high quarterly free cash flow is $298.00 K
What is Y-mAbs Therapeutics quarterly FCF year-on-year change?
Over the past year, YMAB quarterly free cash flow has changed by +$8.79 M (+82.47%)
What is Y-mAbs Therapeutics TTM free cash flow?
The current TTM FCF of YMAB is -$15.71 M
What is the all time high TTM FCF for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high TTM free cash flow is -$6.61 M
What is Y-mAbs Therapeutics TTM FCF year-on-year change?
Over the past year, YMAB TTM free cash flow has changed by +$6.17 M (+28.18%)